[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National and Kapodistrian University of Athens\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":734},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,61,93,117,141,169,198,227,252,282,316,346,375,405,437,468,493,518,541,566,593,618,638,669,694],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":34,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100641855","human-pilot-study-for-the-investigation-of-the-role-of-bilberry-and-olive-bioactives-on-oxidative-stress-parameters-and-inflammatory-markers-100641855",false,"NCT07659028","Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers.","A Blinded Placebo-controlled Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers. Relevance in European Population","BIOTRANSFORM","Inclusion Criteria:\n\n* 30-50 years old,\n* BMI\\> 25 kg\u002Fm2\n* prediabetic stage\n* hsCRP\\> 2mg\u002F L\n* HbA1c 5,7-6,4%\n* Impaired fasting glucose (IFG)\n* Caucasian\n\nExclusion Criteria:\n\n* No signed informed consent\n* Supplementation or probiotic usage in the past 8 weeks\n* Chronic gastrointestinal, inflammatory or metabolic diseases\n* Alcohol misuse\n* Pregnancy or breastfeeding\n* Acute infection during the past month",true,"ALL","30 Years","50 Years",{"count":23,"type":24},60,"ESTIMATED","INTERVENTIONAL",[27],"NA","Numerous plant-based foods contain bioactive compounds, in particular polyphenols, which have antioxidant, anti-inflammatory, and metabolic regulatory effects. These so-called food bioactives (FB) are converted in the human organism, in particular by the gut microbiota and microsomal (liver\u002Fintestinal) metabolism, into numerous metabolites, which often represent the actual biologically active molecules. As part of the European HORIZON-MSCA Doctoral Network \"BioTransform,\" two such food models are being studied as examples: 1. Olive products (Olea europaea L.) - representative of the Mediterranean diet, rich in secoiridoids and phenylethanols (especially hydroxytyrosol and tyrosol). 2.\n\nBilberry \u002Fblueberry (Vaccinium myrtillus L.) - representative of the Central European diet, rich in anthocyanosides. Two parallel human intervention studies will be conducted, one in Graz (WP1, DC5) and one in Athens (WP1, DC3). These pilot studies will generate biological samples (blood, urine, stool) and investigate the extent to which taking these standardized dietary supplements influences glucose metabolism and markers of oxidative stress and low-grade inflammation.",[30,31,32,33],"Prediabetes","Obesity & Overweight","Inflamation","Oxidative Stress",[35,36,37,38,39,40,41,42,43,44,45,46,47],"FOOD BIOACTIVES","FOOD BIOACTIVE COMPOUNDS","OLIVE PRODUCTS","BILBERRY PRODUCTS","OLEA EUROPEA L.","BILBERRY","VACCINUM MYRTILLOUS L.","GUT MICROBIOME","MICROBIOME MAPPING","IN VITRO","IN SILICO","BIOACTIVE COMPOUNDS","METABOLISM","NOT_YET_RECRUITING","2026-06-15",{"date":51,"type":52},"2026-06-22","ACTUAL",{"date":54,"type":24},"2026-07-01",{"date":56,"type":24},"2029-10-31",{"name":58,"class":59},"National and Kapodistrian University of Athens","OTHER",1,{"id":62,"slug":63,"hasResults":12,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":4,"enrollmentInfo":70,"targetDuration":72,"studyType":73,"phases":4,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":60},"100642092","precision-obesity-medicine-genetic-prediction-of-response-to-glp-1gip-agonists-100642092","NCT07653412","Precision Obesity Medicine: Genetic Prediction of Response to GLP-1\u002FGIP Agonists.","Prediction of Response to GLP-1\u002FGIP Receptor Agonists in Obesity Using Genetic Risk Score and SNP Profiling: A Prospective Cohort Study.","Diagenix","Inclusion Criteria:\n\nAge ≥18 years BMI ≥40 kg\u002Fm² or ≥37 kg\u002Fm² with comorbidities Initiation of semaglutide or tirzepatide\n\nExclusion Criteria:\n\nPrior bariatric surgery Secondary causes of obesity Active malignancy Chronic pancreatitis Family history of medullary thyroid carcinoma","18 Years",{"count":71,"type":24},220,"6 Months","OBSERVATIONAL","Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)\u002FGLP-1 receptor agonists, such as tirzepatide, are highly effective treatments for obesity, substantial inter-individual variability in weight loss response remains. Genetic factors may contribute to these differences in treatment outcomes.\n\nThe aim of this prospective cohort study is to investigate whether a Genetic Risk Score (GRS) and selected obesity-related single nucleotide polymorphisms (SNPs) can predict weight loss response to semaglutide or tirzepatide in adults with obesity. Participants initiating treatment with either medication will undergo clinical, biochemical, and genetic assessment at baseline and will be followed for six months. The study will evaluate the association between genetic markers and treatment response and develop predictive models integrating genetic and clinical variables. The findings may contribute to the development of personalized treatment strategies for obesity.",[76,77,78],"Obesity (Disorder)","Anti-obesity Agents","Precision Medicine",[80,81,78,82,83],"Obesity","Genetic Risk Score","GLP-1 Receptor Agonist","GIP\u002FGLP-1 Receptor Agonist","RECRUITING","2026-06-12",{"date":87,"type":52},"2026-06-17",{"date":89,"type":52},"2026-04-22",{"date":91,"type":24},"2027-06-30",{"name":58,"class":59},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":25,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":60},"100640282","phase-2-anifrolumab-in-adults-with-primary-antiphospholipid-syndrome-anifaps-trial-100640282","NCT07584083","Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)","A Phase II Open-Label Pilot Trial Assessing the Safety of Anifrolumab in Adult Patients With Primary Antiphospholipid Syndrome (APS). The AnifAPS Trial","AnifAPS","Inclusion Criteria:\n\n1. Provision of written informed consent (ICF) prior to any study-specific procedures.\n2. Females\u002Fmales aged 18 to 70 years at Screening (at the time of ICF signing).\n3. Weight ≥40.0 kg at Screening.\n4. Classified as having primary APS as per the 2023 ACR\u002FEULAR APS classification criteria, i.e. fulfilling at least one documented clinical criterion \\[ie., macrovascular (venous thromboembolism and\u002For arterial thrombosis), established microvascular (livedoid vasculopathy, aPL nephropathy, pulmonary haemorrhage or myocardial disease), cardiac valve (valve thickening or valve vegetation) and\u002For haematology (thrombocytopenia)\\] and at least one laboratory criterion and scoring at least three points in each of the clinical and laboratory domains.\n\n   Note: Patients with obstetric manifestations will be excluded from this study.\n5. For females of childbearing potential only: Negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test at Screening.\n6. Females of childbearing potential must be willing to use a highly effective method of contraception (failure rate of \\\u003C1% per year when used consistently and correctly) throughout their participation in the study, i.e., from Screening and for up to 20 weeks after the last dose of IP. Examples of highly effective methods of contraception are located in Appendix C, Contraceptive and Barrier Guidance.\n7. Male patients who are sexually active with a female partner of childbearing potential must be willing to use a condom (with spermicide where commercially available) throughout their participation in the study, i.e., from Screening and for up to 20 weeks after the last dose of IP.\n8. Male patients must not donate sperm during the course of the study and for up to 20 weeks after the last dose of the IP.\n9. Meeting all the following TB criteria:\n\n   1. No history of latent or active TB prior to Screening, except for latent TB with documented completion of appropriate treatment as per local SoC Note: Subjects with no history of latent TB prior to the initial Screening visit, but who are diagnosed with latent TB during the Screening Period, may be considered eligible if appropriate treatment is initiated prior to first administration of IP as per local SoC. Such subjects may be re-screened if necessary to allow for local guidelines on latent TB treatment initiation.\n   2. No signs or symptoms suggestive of active TB from medical history or physical examination\n   3. No recent contact with a person with active TB OR if there has been such contact, referral to a physician specialising in TB to undergo additional evaluation prior to first administration of IP (documented appropriately in source), and, if warranted, receipt of appropriate treatment for latent TB at or prior to first administration of IP as per local SoC.\n   4. Must meet 1 of the following criteria:\n\n   (i)Negative QuantiFERON-TB Gold (QFT-G) test result for TB obtained within 4 weeks prior to Week 0 (Day 1) OR (ii)Positive QFT-G test result for TB obtained during the Screening Period for which active TB has been ruled out and appropriate treatment for latent TB has been initiated prior to first administration of IP as per local SoC OR (iii)Indeterminate (confirmed on retest) QFT-G test result for TB obtained during the Screening Period with ongoing QFT-G testing for TB as clinically indicated.\n10. Chest x-ray \\[or lung CT\\*, where available\\] with no evidence of current active infection (eg, TB) or previous old active TB, malignancy, or clinically significant abnormalities (unless due to APS) obtained during the Screening Period or anytime within 12 weeks prior to signing the ICF.\n11. Negative SARs-CoV-2 polymerase chain reaction (PCR) or antigen test result as per local policies at Screening.\n12. Females with an intact cervix must have documentation of a normal Pap smear with no documented malignancy (e.g., cervical intraepithelial neoplasia grade III \\[CIN III\\], carcinoma in situ \\[CIS\\], or adenocarcinoma in situ \\[AIS\\]) within 2 years prior to Week 0 (Day 1) (see Appendix E for guidance on abnormal Pap smear results).\n\nNote: Any abnormal Pap smear result documented within 2 years prior to randomisation must be repeated to confirm patient eligibility. See also Exclusion criterion 23b.\n\nExclusion Criteria:\n\n* General exclusion criteria:\n\n  1. Any condition that, in the opinion of the Investigator, would interfere with the efficacy or safety evaluation of the study intervention or put the participant at safety risk.\n  2. Involvement in the planning and\u002For conduct of the study (applies to both Investigator staff and\u002For staff at the study site).\n  3. Current participation in another clinical study with an IP.\n  4. Lactating or pregnant females or females who intend to become pregnant anytime from initiation of Screening through the Safety Follow-up Period (12 weeks following last dose of IP).\n  5. Current alcohol, drug or chemical abuse, or a history of such abuse within 12 months prior to Week 0 (Day 1).\n  6. Major surgery within 8 weeks prior to Screening or elective major surgery planned anytime from initiation of Screening through the Safety Follow-up Period (12 weeks following last dose of IP).\n  7. Spontaneous or induced abortion, still or live birth, or pregnancy ≤4 weeks prior to Screening.\n  8. Any of the following laboratory abnormalities at Screening (within 4 weeks prior to Week 0 \\[Day 1\\]):\n\n     * aspartate aminotransferase (AST) \\>2.5 x upper limit of normal (ULN)\n     * alanine aminotransferase (ALT) \\>2.0 x ULN\n     * total bilirubin \\> ULN (unless due to Gilbert's syndrome)\n     * serum creatinine \\>2.5 mg\u002FdL (or \\>181 μmol\u002FL)\n     * urine protein\u002Fcreatinine ratio (UACR) \\>2.0 mg\u002Fmg (or \\>226.30 mg\u002Fmmol)\n     * neutrophil count \\\u003C1000\u002FμL (or \\\u003C1.0 x 109\u002FL)\n     * PLT \\\u003C25000\u002F μL (or \\\u003C25 x 109\u002FL)\n     * haemoglobin \\\u003C8 g\u002FdL (or \\\u003C80 g\u002FL)\n     * glycosylated haemoglobin (HbA1c) \\>8% (or \\>0.08) for diabetic subjects only Note: Abnormal screening laboratory tests may be repeated once on a separate sample before the subject is declared a screen failure.\n  9. Major surgery within 8 weeks prior to Screening or elective major surgery planned anytime from initiation of Screening through the Safety Follow-up Period (12 weeks following last dose of IP).\n\n     Exclusion criteria related to APS and\u002For other medical conditions\u002Fdiseases:\n  10. Meeting ACR\u002FEULAR classification criteria for SLE or other systemic autoimmune diseases.\n  11. History or current diagnosis of catastrophic APS within 12 months prior to Screening.\n  12. Any medical or psychiatric condition (including severe or unstable neuropsychiatric APS) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study.\n  13. Current evidence of moderately severe depression as indicated by a score ≥15 in the PHQ-9 questionnaire at Screening.\n  14. Known history of suicidal behaviour in the past 12 months prior to Screening or current evidence of suicidal ideation as indicated by a positive response (i.e., selecting 1: \"Several days\", 2: \"More than half the days\" or 3: \"Nearly every day\") to Question 9 of the PHQ-9 questionnaire irrespective of total score at Screening.\n\n      Exclusion criteria related to infection and malignancy risk factors:\n  15. Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the subject to infection or a positive result for humanimmunodeficiency virus (HIV) antibody or infection confirmed by the local laboratory at Screening.\n\n      Note: An HIV test must be performed during the Screening Period, and the result should be available prior to Week 0 (Day 1). Patients refusing to perform HIV testing during the Screening Period will be excluded from study participation.\n  16. Confirmed seropositivity for hepatitis B at Screening, i.e.:\n\n      1. Positive result for hepatitis B surface antigen (HBsAg), OR\n      2. Positive result for hepatitis B core antibody (HBcAb) AND hepatitis B virus (HBV) DNA detected above the lower limit of quantification (LLQ) by reflex testing by the local laboratory.\n\n      Note: Patients who are HBcAb-positive at Screening will be tested every 3 months for HBV DNA. To remain eligible for the study, the patient's HBV DNA levels must remain below the LLQ as per the local laboratory.\n  17. Positive result for hepatitis C antibody at Screening.\n  18. Any severe herpes zoster infection at any time prior to Week 0 (Day 1), including but not limited to, non-cutaneous herpes (ever), herpes encephalitis (ever), recurrent herpes zoster (defined as 2 episodes within 2 years) or ophthalmic herpes involving the retina (ever).\n  19. Any herpes zoster, cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection that has not completely resolved within 12 weeks prior to Screening.\n  20. Any history of severe COVID-19 infection or any prior COVID-19 infection with documented long-COVID and\u002For clinically significant unresolved sequelae within 12 months prior to Week 0 (Day 1) or mild\u002Fasymptomatic acute COVID-19 infection (lab confirmed or suspected based on clinical signs\u002Fsymptoms) within 6 weeks prior to Week 0 (Day 1).\n  21. Any opportunistic infection requiring hospitalisation or treatment with IV antibiotics within 3 years prior to Screening.\n  22. Any of the following:\n\n      1. Clinically significant chronic infection (e.g. osteomyelitis, bronchiectasis, etc.) within 8 weeks prior to Week 0 (Day 1) (chronic nail infections are allowed)\n      2. Any infection requiring hospitalization or treatment with IV antibiotics not completed at least 4 weeks prior to Week 0 (Day 1)\n  23. Any infection requiring oral antibiotics (including antivirals) within 2 weeks prior to Week 0 (Day 1).\n  24. History of malignancy except for:\n\n      1. squamous or basal cell carcinoma of the skin with documented success of curative therapy of ≥3 months prior to Week 0 (Day 1), OR\n      2. cervical cancer in situ (CIS) treated with documented success of curative therapy ≥12 months prior to Week 0 (Day 1)\n\n      Exclusion criteria related to prior\u002Fconcomitant medications:\n  25. Currently receiving direct oral anticoagulants (DOACs).\n  26. Prior treatment with any of the following:\n\n      * anifrolumab\n      * any investigational product (small molecule or biologic agent) within 90 days or 5 half-lives prior to Screening, whichever is greater\n      * any commercially available biologic agent, including but not limited to B-cell depleting therapies \\[i.e. rituximab, other anti-CD20, anti-CD22 or anti-CD38 agents\\], anti-TNF-α agents, belimumab, abatacept or any other, within 90 days or 5 half-lives prior to Screening, whichever is greater\n      * any commercially available protein kinase inhibitor including but not limited to Janus kinase (JAK) inhibitors or Bruton's tyrosine kinase (BTK) inhibitors within 90 days or 5 half-lives prior to Screening, whichever is greater\n      * conventional immunomodulators or immunosuppressants (e.g., cyclophosphamide, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, etc.) or IV immunoglobulin within 90 days prior to Screening\n      * intraarticular, intramuscular, or intravenous corticosteroids within 30 days prior to Screening.\n      * any live or attenuated vaccine within 8 weeks prior to Screening.\n  27. Current treatment with oral corticosteroids except for patients with severe thrombocytopenia or pulmonary haemorrhage who have started oral corticosteroids (up to 40 mg\u002Fday prednisone or equivalent) within 30 days Week 0 (Day 1).\n  28. Blood transfusion or receipt of blood products within 4 weeks prior to Screening.\n  29. Known history of allergy or reaction to any component of the IP formulation or history of anaphylaxis to any human gamma globulin therapy.\n\nFor procedures for withdrawal of incorrectly enrolled subjects, see Section 3.4.","70 Years",{"count":103,"type":24},20,[105],"PHASE2","This is a phase II, single-centre, open-label pilot study evaluating the safety and tolerability of anifrolumab in adult patients with primary antiphospholipid syndrome (APS). Approximately 20 participants will receive 120 mg subcutaneous anifrolumab once weekly for up to 52 weeks in addition to their standard of care treatment.\n\nThe primary objective is to assess the incidence of adverse events during treatment. Secondary and exploratory objectives include evaluation of immunological parameters, thromboinflammatory markers, and patient-reported outcomes. Participants will be followed for an additional 12-week safety follow-up period after completion of treatment.",[108],"Antiphospholipid Syndrome (APS)","2026-05-30",{"date":111,"type":52},"2026-06-02",{"date":113,"type":52},"2026-04-29",{"date":115,"type":24},"2028-06",{"name":58,"class":59},{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":25,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100640127","augmentation-of-arthroscopic-rotator-cuff-repair-with-reimplantation-of-subacromial-bursa-tissue-and-platelet-rich-plasma-100640127","NCT07589478","Augmentation of Arthroscopic Rotator Cuff Repair With Reimplantation of Subacromial Bursa Tissue and Platelet-Rich Plasma","ΕΝΙΣΧΥΣΗ ΑΡΘΡΟΣΚΟΠΙΚΗΣ ΣΥΡΡΑΦΗΣ ΣΤΡΟΦΙΚΟΥ ΠΕΤΑΛΟΥ ΜΕ ΕΠΑΝΕΜΦΥΤΕΥΣΗ ΙΣΤΟΥ ΤΟΥ ΥΠΑΚΡΩΜΙΑΚΟΥ ΘΥΛΑΚΟΥ ΚΑΙ ΠΛΑΣΜΑΤΟΣ ΠΛΟΥΣΙΟΥ ΣΕ ΑΙΜΟΠΕΤΑΛΙΑ","Inclusion Criteria Adult patients aged ≥18 years. Patients undergoing arthroscopic rotator cuff repair. Patients with a full-thickness, isolated, primary tear of the supraspinatus tendon.\n\nPatients considered eligible for arthroscopic rotator cuff repair using suture anchors.\n\nAbility and willingness to provide written informed consent. Willingness and ability to comply with the study protocol and scheduled follow-up visits.\n\nExclusion Criteria Partial-thickness rotator cuff tears. Massive or irreparable rotator cuff tears. Revision rotator cuff repair. Concomitant tears of the subscapularis tendon, infraspinatus tendon, long head of the biceps tendon requiring surgical treatment, or glenoid labrum.\n\nPrevious surgery on the affected shoulder. Glenohumeral osteoarthritis or advanced cuff tear arthropathy. Active infection or systemic inflammatory disease affecting the shoulder. Use of other biological augmentation techniques during surgery, such as collagen patch, stem cells, bone marrow aspirate concentrate, or other scaffold-based augmentation.\n\nInability to provide informed consent. Inability or unwillingness to comply with the postoperative rehabilitation protocol or follow-up schedule.",{"count":125,"type":24},200,[27],"The goal of this observational study is to evaluate the clinical and radiographic outcomes of the biological enhancement of the arthroscopic rotator cuff repair with stem cells from the acromial bursa and PRP in individuals who undergo arthroscopic cuff repair The main question it aims to answer is:\n\nDo the stems cells from the acromial bursa and PRP promote healing and produce better results in arthroscopic cuff repair? Researchers will compare this population to three others the first do bnot receive any biological enchancement, the second receive only stem cells and the third receive only PRP to see if there are any differences.",[129,130,131,132],"Cuff Injury, Rotator","Arthroscopic Surgical Procedures","Stem Cell","PRP","2026-05-17",{"date":135,"type":52},"2026-05-19",{"date":137,"type":24},"2026-05",{"date":139,"type":24},"2028-02",{"name":58,"class":59},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":25,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":168,"locationsCount":4},"100635121","a-long-axis-approach-to-the-femoral-artery-block-fab-for-managing-tourniquet-pain-and-hypertension-in-below-the-knee-fracture-surgery-100635121","NCT07548567","A Long Axis Approach to the Femoral Artery Block (FAB) for Managing Tourniquet Pain and Hypertension in Below-the-Knee Fracture Surgery","Turning the Probe, Changing the View: A Novel Long Axis Approach to the Femoral Artery Block (FAB) for Managing Tourniquet Pain and Hypertension in Below-the-Knee Fracture Surgery: A Prospective, Randomized, Double-Blind Controlled Trial","FAB","Inclusion Criteria:\n\n* Age \\>18 years\n* Physical status ASA I-III\n* Fluent in Greek or English\n* Scheduled surgery: below-knee fractures\n* Tourniquet duration ≥45 minutes\n\nExclusion Criteria:\n\n* Refusal to participate\n* Local inflammation at block site\n* Known allergy to study drugs\n* Morbid obesity (BMI \\>40)\n* Communication inability\n* Systemic neurological disease affecting peripheral nerves\n* Chronic pain therapy\n* Diabetic neuropathy\n* Uncontrolled hypertension",{"count":150,"type":24},84,[27],"This is a prospective, randomized, double-blind controlled trial evaluating an ultrasound-guided femoral artery block (FAB) using a long-axis in-plane approach compared with a short-axis approach and a control group.\n\nThe study will include adult patients (ASA I-III) undergoing below-the-knee fracture surgery with tourniquet application. All patients will receive standardized anesthesia including sciatic nerve block and total intravenous anesthesia.\n\nParticipants will be randomized into three groups: short-axis FAB, long-axis FAB, or control (saline injection). The primary aim is to assess the effectiveness of the long-axis FAB in reducing tourniquet-induced hypertension. Secondary outcomes include hemodynamic stability, analgesic requirements, pain scores, block characteristics, and procedural performance metrics.",[154],"Tourniquet Hypertension",[156,157,158,159,160,161,162,163],"FAB block","Tourniquet-induced hypertension","Tourniquet pain","Below-knee fracture surgery","Sympathetic blockade","intraoperative hypertension","sciatic nerve block","randomized controlled trial",{"date":165,"type":52},"2026-04-30",{"date":137,"type":24},{"date":139,"type":24},{"name":58,"class":59},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":25,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":60},"100616107","hypotension-prediction-index-hpi-and-assisted-fluid-management-afm-for-perioperative-hemodynamic-optimization-in-patients-under-general-anesthesia-100616107","NCT07301307","Hypotension Prediction Index (HPI) and Assisted Fluid Management (AFM) for Perioperative Hemodynamic Optimization in Patients Under General Anesthesia","The Use of the Hypotension Prediction Index (HPI) Combined With the Assisted Fluid Management (AFM) Software for Perioperative Hemodynamic Optimization in Patients Undergoing General Anesthesia.","Inclusion Criteria:\n\n* Age \\> 18 years\n* Intraoperative monitoring \\> 2 hours or general anesthesia \\> 2 hours\n* Invasive arterial pressure monitoring\n* Target MAP ≥ 65 mm Hg intraoperatively\n* Written informed consent preoperatively\n* ASA Physical Status ≤ 4\n\nExclusion Criteria:\n\n* Target MAP other than 65 mm Hg\n* Severe preoperative hypotension (MAP \\\u003C 65 mm Hg)\n* Severe heart failure (e.g. LVEF \\\u003C 20%)\n* Emergency surgery",{"count":177,"type":24},100,[27],"This study investigates if the Hypotension Prediction Index (HPI) combined with the Assisted Fluid Management (AFM) software can improve perioperative hemodynamic management in adult patients undergoing general anesthesia. The main question is :\n\nDoes the HPI and AFM software reduce the incidence and duration of intraoperative hypotension? Does the HPI and AFM software optimize fluid and vasopressor administration? Does the HPI and AFM software improve perioperative outcomes? Participants will be randomly allocated to either an experimental group receiving goal directed hemodynamic therapy guided by HPI and AFM or a control group receiving conventional hemodynamic management.",[181],"Intraoperative Hypotension",[181,183,184,185,186,187,188,189],"Perioperative Hemodynamic Optimization","Goal-Directed Hemodynamic Therapy","Hypotension Prediction Index","Assisted Fluid Management","Invasive Arterial Pressure Monitoring","Artificial Intelligence","Perioperative Care","2026-04-16",{"date":192,"type":52},"2026-04-20",{"date":194,"type":52},"2026-03-15",{"date":196,"type":24},"2027-03",{"name":58,"class":59},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":18,"sex":19,"minAge":69,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":25,"phases":208,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":60},"100508400","comparison-of-the-effectiveness-of-two-different-surgical-therapeutic-protocols-of-peri-implantitis-100508400","NCT05899933","Comparison of the Effectiveness of Two Different Surgical Therapeutic Protocols of Peri-implantitis","Implantoplasty Versus Implant Decontamination With Erythritol Air-abrasive Device During Surgical Therapy of Peri-implantitis. Clinical, Radiographic and Microbiological Evaluation. A Randomized Controlled Clinical Study","Inclusion Criteria:\n\nGeneral Inclusion Criteria:\n\n* Participants ≥ 18 years and ≤ 80 years of age\n* Non-smokers based on the patients' self-reported smoking status, defined as patients who had never smoked or had quit smoking at least 2 years ago\n* Implants in function for more than 1 year after suprastructure connection\n\nInclusion Criteria for implants diagnosed with Peri-Implantitis:\n\n* Presence of at least one implant diagnosed with peri-implantitis defined as presence of bleeding on probing and\u002For suppuration, probing pocket depth ≥6 mm and ≥3 mm of detectable bone loss after initial re-modelling\n* Absence of implant mobility\n\n  * in participants with more than one implant, the implant with the worst clinical condition will be studied.\n\nInclusion Criteria for implants diagnosed with Peri-Implant Health:\n\n* Absence of peri-implant signs of inflammation (redness, swelling)\n* Lack of bleeding on probing\n* Absence of bone loss beyond crestal bone level changes resulting from initial remodeling, which should not be ≥2 mm\n\nExclusion Criteria:\n\n* Smokers\n* Uncontrolled diabetes mellitus (HBA1c \\>7)\n* Treatment with bisphosphonates\n* Needing antibiotic prophylaxis\n* Currently pregnant or breast-feeding women\n* History of systemic administration of antibiotic treatment during the preceding 3 months\n* Systemic conditions that contraindicate treatment\n* Use of medications known to induce gingival hyperplasia","80 Years",{"count":207,"type":24},45,[27],"The purpose of the present study is to compare the 1-year clinical, radiographic and microbiological outcomes and patients' satisfaction following surgical treatment of peri-implantitis after applying two different surface modification methods. Secondarily, analysis and comparison of the microbiological results of implants diagnosed and treated for peri-implantitis with healthy implants will be performed.",[211,212],"Peri-Implantitis","Peri-Implant Health",[211,214,215,216,217,218],"Surgical therapy","Implantoplasty","Air-abrasive device","Erythritol powder","Peri-Implant microbiota","2026-04-14",{"date":221,"type":52},"2026-04-15",{"date":223,"type":52},"2023-07-28",{"date":225,"type":24},"2026-12",{"name":58,"class":59},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":60},"100571134","effectiveness-of-radiofrequency-ablation-and-stabilization-in-metastatic-spine-lesions-by-positron-emission-computed-tomography-pet-ct-confirmation-100571134","NCT06716294","Effectiveness Of Radiofrequency Ablation And Stabilization In Metastatic Spine Lesions By Positron Emission Computed Tomography (PET-CT) Confirmation","Effectiveness Of Radiofrequency Ablation And Stabilization In Metastatic Spine Lesions By PET-CT Confirmation","ABLASPINE","Inclusion Criteria:\n\n* only patients with secondary osteolytic and mixed (lytic and sclerotic) spine tumors with one to three active lesions will be enrolled.\n* lesions to be treated must be metabolically active on PET-CT performed during the last month.\n* Patients will be informed and sould sign an inform consent.\n* post treatment patients should submittes a new PET-CT in order to verify the activity of the treated area.\n\nExclusion Criteria:\n\n\\-","90 Years",{"count":237,"type":24},16,"This pilot study will try to demonstrate metabolic changes in spine lesions treated by Augmentation and Ablation, according to existing standards of practice. Our purpose is to show the efficacy of a new radiofrequency ablation (RFA) in combination with augmentation, using a percutaneous ablation device (Osteocool-Medtronic) in the treatment of secondary vertebral bone tumor, avoiding concurrent bias related to other treatments of the disease.",[240,241,242,243],"Bone Cancer Metastatic","Radiofrequency Ablation","Spine Metastases","Vertebral Metastasis","2026-04-06",{"date":246,"type":52},"2026-04-09",{"date":248,"type":52},"2023-01-01",{"date":250,"type":24},"2028-12-31",{"name":58,"class":59},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":4,"enrollmentInfo":260,"targetDuration":261,"studyType":73,"phases":4,"briefSummary":262,"conditions":263,"keywords":267,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":60},"100629655","recurrence-and-anal-fistula-patient-reported-outcomes-trial-100629655","NCT07477496","Recurrence and Anal Fistula Patient Reported Outcomes Trial","Prospective Study of Functional Disorders and Quality of Life Following Surgical Management of Perianal Fistulas","RAPPORT","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinically and\u002For radiologically confirmed perianal fistula (primary or recurrent).\n* Planned definitive surgical treatment (any sphincter-dividing or sphincter-preserving technique).\n* Ability to understand and complete study questionnaires.\n* Commitment to attend follow-up visits at 1, 3, 6, and 12 months (or to complete remote assessments).\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Diagnosed inflammatory bowel disease (Crohn's disease or ulcerative colitis).\n* Active perianal sepsis requiring emergency drainage after enrolment and before definitive surgery.\n* Prior abdominoperineal resection or permanent colostomy.\n* Pregnancy or planned pregnancy during the 12-month follow-up.\n* Severe uncontrolled systemic disease (e.g., decompensated heart failure, end-stage renal disease, uncontrolled diabetes).\n* Cognitive impairment or psychiatric disorder precluding reliable consent or questionnaire completion.\n* Lack of reliable contact information or inability to attend at least one scheduled follow-up visit.",{"count":177,"type":24},"24 Months","Perianal fistulas are a chronic anorectal condition associated with significant morbidity, including pain, persistent discharge, infection, and impaired continence, all of which can substantially affect patients' quality of life. Surgical management aims to eradicate the fistulous tract while preserving anal sphincter function and continence.\n\nDespite numerous available surgical techniques, high-quality comparative evidence regarding optimal management remains limited. This prospective observational study aims to evaluate clinical outcomes, functional outcomes, and patient-reported quality of life following surgical treatment of perianal fistulas.\n\nThe study will collect both clinician-reported and patient-reported outcomes over a 12-month follow-up period. Outcomes of interest include fistula healing, recurrence, postoperative complications, continence status, symptom burden, and health-related quality of life. The findings are expected to provide real-world data that may inform clinical decision-making and contribute to improved patient-centered care.",[264,265,266],"Anal Fistula Surgery","Anal Fistula","Perianal Fistula",[268,269,270,271,272,273],"perianal","fistula","anal","PROMs","patient-reported outcomes","quality of life","2026-03-17",{"date":276,"type":52},"2026-03-19",{"date":278,"type":52},"2026-01-01",{"date":280,"type":24},"2030-01-01",{"name":58,"class":59},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":25,"phases":291,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":60},"100624327","early-phase-1-the-role-of-coadministration-of-lidocaine-and-ketamine-in-opioid-refractory-chronic-cancer-related-pain-100624327","NCT07408193","The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.","The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain: a Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Trial.","Inclusion Criteria:\n\n* Age 18 years or more\n* Capacity to provide informed consent, ability to complete study assessments and comply with the study procedures\n* Meets the IASP definition for chronic cancer-related pain\n* Moderate or severe pain, defined as average pain of 4 or greater on an 11-point (0-10) NRS in the past 24h\n* Adequate trial of opioid medication, defined as a dose of at least 60 mg\u002Fday oral morphine equivalent or maximum tolerated dose, in the past 24h\n* For patients with neuropathic component to pain: adequate trial of at least one adjuvant analgesic, defined as a daily dose of at least Amitriptyline 37.5mg, Duloxetine 30mg, Gabapentin 900mg, Pregabalin 150mg, Venlafaxine 60mg or equivalent (26), or maximum tolerated dose in the past 24h\n\nExclusion Criteria:\n\n* Previous adverse reaction to ketamine, lidocaine or other amide-type local anesthetics, midazolam\n* Severe liver disease (Child Class B or C)\n* SGPT or SGOT \\>5 times the upper limit of normal\n* End stage kidney disease\n* Serious cardiac comorbidity (e.g. unstable angina, poorly controlled hypertension or tachycardia, high-risk coronary vascular disease, symptomatic heart failure with NYHA class III-IV, history of heart block, Wolf-Parkinson-White syndrome, Adams-Stokes syndrome)\n* Elevated intracranial or intraocular pressure\n* Pheochromocytoma or poorly controlled hyperthyroidism\n* History of psychosis, schizophrenia or substance abuse\n* Pregnant or breastfeeding\n* Porphyria\n* Life expectancy shorter than the duration of the study",{"count":290,"type":24},24,[292],"EARLY_PHASE1","This is a randomized, double-blinded, placebo-controlled, cross-over trial examining the effect of a series of two weekly intravenous infusions of lidocaine 4 mg\u002Fkg and ketamine 0.2 mg\u002Fkg in patients with moderate to severe opioid-refractory chronic cancer-related pain. The aim of this study is to investigate whether the lidocaine - ketamine (LK) regimen provides better analgesia that an active placebo of midazolam 0.02 mg\u002Fkg, in this population.",[295],"Opioid-Refractory Chronic Cancer-Related Pain",[297,298,299,300,301,302,303,304,305,306,307],"Cancer Pain","Treatment-Resistant Chronic Pain","Lidocaine","Ketamine","Analgesics, Adjuvant","Infusions, Intravenous","Cross-Over Studies","Double-Blind Method","Patient Reported Outcome Measures","Opioid-Related Disorders","Neoplasms","2026-02-18",{"date":310,"type":52},"2026-02-20",{"date":312,"type":24},"2026-03",{"date":314,"type":24},"2027-08",{"name":58,"class":59},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":4,"enrollmentInfo":324,"targetDuration":325,"studyType":73,"phases":4,"briefSummary":326,"conditions":327,"keywords":332,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":343,"leadSponsor":345,"locationsCount":60},"100624064","hemorrhoid-suture-mucopexy-combined-with-laser-hemorrhoidoplasty-100624064","NCT07404774","Hemorrhoid Suture Mucopexy Combined With Laser Hemorrhoidoplasty","Prospective Evaluation of Hemorrhoid Suture Mucopexy (SM) Combined With Laser Hemorrhoidoplasty (LHP) for Symptomatic Hemorrhoidal Disease: A Cohort Study","HeMuLa","Inclusion Criteria:\n\n* Adults (\\>18 years).\n* Symptomatic Hemorrhoidal Disease (Goligher Grades II, III, IV).\n* Patients with or without recurrent disease after prior procedures (e.g., RBL, infrared coagulation, Milligan-Morgan, etc).\n\nExclusion Criteria:\n\n* Acutely thrombosed hemorrhoids.\n* Concomitant anal fistula or abscess requiring separate surgical management.\n* IBD (Crohn's\u002FUlcerative Colitis) with active rectal involvement.\n* Previous Stapled Haemorrhoidopexy (SH\u002FLongo).",{"count":177,"type":24},"12 Months","This prospective cohort study evaluates whether combining \"suture mucopexy\" (a simple stitch-based lift of prolapsed tissue) with Laser Hemorrhoidoplasty (LHP) can effectively relieve pain, bleeding and prolapse in adults with moderate-to-severe hemorrhoids (Grades II-IV). Participants will undergo the combined, non-Doppler-guided procedure and be followed for one year. The primary question is how long patients need post-operative pain medication and if they first experience complete symptom relief; secondary questions examine quality-of-life, safety (bleeding, urinary retention, stenosis) and the rate of hemorrhoid recurrence\u002Fre-operation.",[328,329,330,331],"Haemorrhoid","Haemorrhoidal Bleeding","Anorectal Surgeries","Anorectal Diseases",[333,334,335,336,337,338],"haemorrhoid","laser","mucopexy","suture mucopexy","LHP","haemorrhoidoplasty","2026-02-08",{"date":341,"type":52},"2026-02-11",{"date":278,"type":52},{"date":344,"type":24},"2029-01",{"name":58,"class":59},{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":4,"enrollmentInfo":353,"targetDuration":355,"studyType":73,"phases":4,"briefSummary":356,"conditions":357,"keywords":360,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":374},"100622883","a-prospective-multicenter-registry-to-observe-the-treatment-patterns-clinical-outcomes-and-decision-making-in-patients-with-early-breast-cancer-eligible-for-endopredict-testing-100622883","NCT07389408","A Prospective, Multicenter Registry to Observe the Treatment Patterns, Clinical Outcomes, and Decision-Making in Patients With Early Breast Cancer Eligible for EndoPredict® Testing","PRELUDE","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Histological diagnosis of invasive breast cancer.\n* T1-T3 tumor size.\n* 0-3 positive axillary lymph nodes.\n* Documented ER-positive tumor by immunohistochemistry (≥1% or Allred Score: ≥3\u002F8 or H-score: ≥50\u002F 300)\n* Documented HER2-negative tumor by immunohistochemistry and\u002For in situ hybridization\n* Subject with signed and dated informed consent form.\n\nExclusion Criteria:\n\n* History of another primary malignancy within the last 5 years, except for resected non-melanoma skin cancer.\n* Pre-operative chemotherapy administered.\n* Subject without signed and dated informed consent form.",{"count":354,"type":24},2000,"10 Years","The study is planned to observe and document the therapeutic decision-making process, treatment protocols, and clinical outcomes in patients with luminal breast cancer, whether they have undergone EndoPredict® testing or not",[358,359],"Breast Cancer","Breast Adenocarcinoma",[361,362,363,364,365],"breast cancer","luminal subtype","EndoPredict","genetic signature","survival","2026-01-31",{"date":368,"type":52},"2026-02-05",{"date":370,"type":52},"2025-04-01",{"date":372,"type":24},"2038-12-31",{"name":58,"class":59},13,{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":4,"enrollmentInfo":383,"targetDuration":72,"studyType":73,"phases":4,"briefSummary":385,"conditions":386,"keywords":390,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":404},"100622190","transulnar-access-in-patients-with-ipsilateral-radial-artery-occlusion-undergoing-coronary-angiography-or-angioplasty-100622190","NCT07380399","Transulnar Access in Patients With Ipsilateral Radial Artery Occlusion Undergoing Coronary Angiography or Angioplasty","Transulnar Access in Patients With Ipsilateral Radial Artery Occlusion Undergoing Coronary Angiography or Angioplasty: Safety and Effect on Hand Function (ULNART)","ULNART","Inclusion Criteria\n\nParticipants must meet all of the following criteria to be eligible:\n\n* Adults aged 18 years or older\n* Documented radial artery occlusion in the upper limb intended for vascular access, confirmed by ultrasound or angiography\n* Scheduled to undergo elective coronary angiography and\u002For angioplasty\n* Transulnar arterial access on the same side as the occluded radial artery is selected by the treating physician\n* Contralateral radial artery access is not feasible or is clinically undesirable, including for reasons such as:\n* documented occlusion or severe disease of the contralateral radial artery\n* unfavorable anatomy or prior failed access\n* strategic preservation of the contralateral radial artery for future surgical or dialysis needs\n* Adequate ulnar artery flow and anatomy for access, as assessed by pre-procedural ultrasound\n* Able and willing to provide written informed consent\n\nExclusion Criteria\n\nParticipants meeting any of the following criteria will be excluded:\n\n* Inadequate or absent ulnar artery flow at the intended access site on ultrasound\n* Known ulnar nerve injury or neuropathy affecting the access-side upper limb\n* Severe pre-existing motor or sensory dysfunction of the access-side hand that would interfere with functional assessment\n* Emergency coronary procedures that preclude baseline vascular or functional assessment\n* Participation in another interventional clinical study involving vascular access or intervention in the same upper limb\n* Local conditions at the intended access site, such as active infection, burn, or extensive scarring\n* Pregnancy or breastfeeding\n* Life expectancy less than 6 months",{"count":384,"type":24},127,"Coronary angiography and angioplasty are commonly performed through the radial artery at the wrist as this approach is associated with fewer bleeding complications and faster recovery. In some patients, the radial artery becomes occluded after prior procedures, requiring selection of an alternative access site for future coronary interventions.\n\nThe ulnar artery is a potential alternative wrist access. However, limited data are available on the safety of using the ulnar artery in the same arm as an occluded radial artery and on the possible effects on hand strength, sensation, and daily hand function.\n\nThe goal of this observational study is to evaluate the safety of transulnar access and its effect on hand function in adults with ipsilateral radial artery occlusion undergoing coronary angiography or angioplasty.\n\nThe main questions addressed by the study are:\n\n* How often do serious access-related vascular or nerve complications occur?\n* Does hand strength, sensation, or functional use of the hand change during follow-up?\n* Does the ulnar artery remain patent after the procedure? The choice of vascular access site is made by the treating physician based on clinical judgment. Participants who undergo transulnar access will undergo follow-up assessments, including ultrasound evaluation of arm arteries, standardized hand function testing, and short questionnaires assessing upper-limb function.\n\nThe findings of this study are expected to inform access-site selection, improve patient counseling, and support safer care for patients with radial artery occlusion undergoing coronary procedures.",[387,388,389],"Radial Artery Occlusion","Vascular Access","Coronary Artery Disease (CAD)",[387,391,392,393,394,395],"Ulnar Artery","Coronary Angiography","Percutaneous Coronary Intervention","Upper Limb Function","Transulnar Access","2026-01-28",{"date":398,"type":52},"2026-02-02",{"date":400,"type":52},"2025-11-01",{"date":402,"type":24},"2032-01",{"name":58,"class":59},2,{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":413,"enrollmentInfo":414,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":416,"conditions":417,"keywords":418,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":60},"100600213","tirzepatide-vs-liraglutide-in-bone-100600213","NCT07094568","Tirzepatide vs Liraglutide in Bone","Comparative Investigation of Changes in Body Composition and Bone Turnover Markers in People With Obesity After Treatment With Tirzepatide Versus Liraglutide. A Prospective Cohort Study.","TiLi-BONE","Inclusion Criteria:\n\n* Adults aged between 30 and 65 years\n* BMI ≥40 kg\u002Fm²\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus (T2DM) and type 1 Diabetes Mellitus (T1DM)\n* Chronic kidney disease\n* Liver failure\n* Heart failure\n* Malignancy coexistence\n* Previous bariatric or gastrointestinal surgery involving intestinal bypass\n* Uncontrolled hypo\u002Fhyperthyroidism\n* Uncontrolled hypo\u002Fhyperparathyroidism\n* Pregnancy and lactation\n* Recent fracture (within 2 years)\n* Rare Metabolic Bone Diseases (e.g., Paget's disease of bone, fibrous dysplasia, osteopetrosis)\n* Inflammatory arthritis\n* Medications which can affect bone markers: bone-anabolic agents, antiresorptive agents, antiandrogenic agents, vitamin K antagonists, antipsychotic agents, contraceptives, glucocorticoids (oral), methotrexate, thiazides, aromatase inhibitors etc)\n* Hemolytic anemia","65 Years",{"count":415,"type":24},72,"This prospective cohort study investigates the effects of tirzepatide versus liraglutide on bone turnover markers and body composition in adults with class 3 obesity, characterised by Body Mass Index (BMI) ≥40 kg\u002Fm². Participants will be followed for 6 months with assessments at baseline, 3 and 6. The primary outcome is the change in bone resorption marker C-terminal telopeptide of type I collagen (CTX) at 3 months. Secondary outcomes include changes in body weight, BMI, bone mineral density (BMD), and body composition. The study aims to clarify the differential impact of weight loss achieved through tirzepatide versus liraglutide on bone metabolism and body composition in adults with obesity.",[76],[419,420,421,422,423,424,425,426,427,428],"obesity","bone metabolism","body composition","lean mass","free fat mass","fat mass","tirzepatide","liraglutide","CTX","P1NP","2026-01-17",{"date":431,"type":52},"2026-01-21",{"date":433,"type":52},"2025-05-23",{"date":435,"type":24},"2026-12-30",{"name":58,"class":59},{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":19,"minAge":413,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":446,"conditions":447,"keywords":451,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":60},"100619912","prediction-of-mortality-and-morbidity-after-hip-fracture-using-monocyte-distribution-width-mdw-100619912","NCT07350785","Prediction of Mortality and Morbidity After Hip Fracture Using Monocyte Distribution Width (MDW)","The Role of Monocyte Distribution Width (MDW) and Other Inflammatory Biomarkers in the Prediction of Mortality and Morbidity in Patients With Hip Fracture","MDW","Inclusion Criteria:\n\n* Patients aged ≥65 years\n* Admission with low-energy hip fracture (femoral neck, intertrochanteric, or subtrochanteric fracture)\n* Admission to General Hospital of Attica KAT\n* Availability of baseline laboratory measurements, including complete blood count with monocyte distribution width (MDW) and inflammatory biomarkers\n\nExclusion Criteria:\n\n* Age \\\u003C65 years\n* High-energy trauma-related hip fractures\n* Pathological fractures",{"count":177,"type":24},"Hip fracture is a common injury in older adults and is often associated with serious complications, longer hospital stays, and increased risk of death. One of the most important causes of poor outcomes after hip fracture surgery is infection, including severe infections such as sepsis. Early identification of patients at higher risk for complications could help improve treatment and survival.\n\nThis study aims to examine whether a blood test parameter called Monocyte Distribution Width (MDW), along with other commonly used inflammatory markers, can help predict complications and survival in elderly patients with hip fracture. MDW is measured as part of a routine complete blood count and has shown promise in the early detection of infection and systemic inflammation.\n\nApproximately 100 patients aged 65 years or older who are admitted to the hospital with a low-energy hip fracture will be included in this study. Blood tests will be performed at hospital admission, after surgery, and at other time points as part of standard clinical care. These tests include routine blood counts and inflammatory markers such as C-reactive protein (CRP), procalcitonin (PCT), antithrombin III, and MDW. No additional invasive procedures are required beyond standard medical care.\n\nResearchers will collect information about each patient's medical history, overall health status, and daily activity level before the fracture. Patients will be followed after surgery to assess complications, length of hospital stay, and survival at 1 month, 3 months, and 1 year.\n\nThe results of this study may help determine whether MDW can be used as a simple and reliable marker to identify patients at higher risk of complications or death after hip fracture. This could support earlier intervention, closer monitoring, and improved care for elderly patients with hip fractures in the future.",[448,449,450],"Sepsis","Osteoporotic Hip Fracture","Hip Fracture",[452,453,454,455,456,457,458,459,450],"Monocyte Distribution Width (MDW)","Geriatric Patients","Inflammatory Biomarkers","Postoperative Mortality","Postoperative Morbidity","C-reactive Protein","Procalcitonin","Antithrombin III","2026-01-10",{"date":462,"type":52},"2026-01-20",{"date":464,"type":52},"2024-12-01",{"date":466,"type":24},"2026-03-01",{"name":58,"class":59},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":18,"sex":475,"minAge":69,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":477,"conditions":478,"keywords":480,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":4},"100615691","assessing-the-influence-of-implant-scanning-techniques-on-the-accuracy-of-maxillary-complete-arch-digital-scans-for-implant-overdentures-a-comparative-clinical-study-100615691","NCT07295899","Assessing the Influence of Implant Scanning Techniques on the Accuracy of Maxillary Complete-Arch Digital Scans for Implant Overdentures: A Comparative Clinical Study","Evaluation of Impact of Implant Scanning Technique on the Accuracy of Maxillary Complete-arch Digital Scans for Implant-supported Overdentures","Inclusion Criteria:\n\n4 implants places in fully edentelous patient that is planned to be treated with implant supported overdenture\n\n\\-\n\nExclusion Criteria:\n\nDiseases \u002F Conditions That Can Contraindicate Dental Treatment\n\n1. Uncontrolled Systemic Conditions\n\n   Dental procedures-especially invasive ones-are often postponed if the condition is not medically stable:\n\n   • Uncontrolled Hypertension\n\n   BP typically \\>180\u002F110 mmHg is considered unsafe for elective dental care.\n\n   Risk: stroke, heart attack during treatment.\n\n   • Uncontrolled Diabetes\n\n   High blood glucose (e.g., \\>300 mg\u002FdL) increases infection risk and poor healing.\n\n   • Uncontrolled Thyroid Disease\n\n   Hyperthyroidism raises risk of thyroid storm, especially with epinephrine.\n2. Recent Major Cardiac Events\n\n   Elective dental treatment is usually deferred for:\n   * Heart attack (MI) within past 6 months\n   * Stroke within past 6 months\n   * Unstable angina\n   * Severe arrhythmias\n   * Decompensated heart failure\n\n   These conditions can make dental stress or anesthesia dangerous.\n3. Infectious Diseases (Active Phase)\n\n   Dental treatment may be delayed to protect the patient or others.\n   * Active Herpetic Lesions (Cold Sores) around the mouth\n   * Active Tuberculosis (TB)\n   * COVID-19 or other acute respiratory infections with fever\n4. Hematologic Disorders\n\n   If blood does not clot properly, dental surgery can be risky.\n\n   • Severe Thrombocytopenia\n\n   Platelets too low for safe extraction or surgery.\n\n   • Hemophilia or bleeding disorders\n\n   Require management with a hematologist first.\n\n   • Patients on certain anticoagulants (e.g., warfarin with very high INR)\n\n   May need medical adjustment before invasive care.\n5. Pregnancy (Certain Situations)\n\n   Most dental care is safe, but some procedures are postponed:\n\n   Elective treatments during 1st trimester\n\n   Avoid certain medications (e.g., some anesthetics, antibiotics, NSAIDs)\n\n   Severe hypertension or pregnancy complications (eclampsia)\n6. Severe Psychiatric Conditions (Unstable)\n\n   When a patient cannot cooperate safely:\n\n   Acute psychosis\n\n   Severe anxiety uncontrolled by medication\n\n   Need medical stabilization vs. dental sedation coordination\n7. Substance Intoxication\n\nDental care is not performed if patient is intoxicated with:\n\nAlcohol\n\nRecreational drugs (especially stimulants like cocaine or meth)\n\nRisk of cardiovascular events or inability to consent.","MALE",{"count":60,"type":24},"Recently different protocols have been developed for the implementation of intraoral scanning in full-arch implant workflows, as horizontal scan body scanning, 1 reverse scanning 2 and scan body systems with an integrated verification jig 3 . The aforementioned approaches are aiming to reduce the inaccuracies related with the implementation of intraoral scanners in full-arch implant cases and to improve the efficiency of the whole digital workflow. However the efficiency of these methods and the parameters that can influence their accuracy, as the design of the scan body have not been investigated.\n\nThe purpose of the present in vivo study is to compare the trueness and the precision of the recorded implant's position, between conventional and novel implant acquisition protocols.",[479],"Maxillary Complete-arch Digital Scans for Implant-supported Overdentures",[481,482,483,484],"Overdenture","Intraoral scanner","Accuracy","Implants","2025-12-16",{"date":487,"type":52},"2025-12-22",{"date":489,"type":24},"2025-12-15",{"date":491,"type":24},"2026-01-15",{"name":58,"class":59},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":18,"sex":19,"minAge":69,"maxAge":4,"enrollmentInfo":500,"targetDuration":4,"studyType":25,"phases":502,"briefSummary":503,"conditions":504,"keywords":507,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":60},"100615696","accuracy-of-intraoral-scan-post-processing-methods-a-clinical-trial-100615696","NCT07295964","Accuracy of Intraoral Scan Post-processing Methods: A Clinical Trial","Influence of AI Driven Software Programs and Digital Occlusal Collision Corrections on the Occlusal Adjustment of 3D-Printed Restorations: A Clinical Trial","Inclusion Criteria:\n\nAge \\> 18 years old Absence of painful temporomandibular disorder Presence of opposing teeth Presence of a stable maximum intercuspation relationship\n\nExclusion Criteria:\n\n\\- Pain in orofacial region Visible periapical lesion \\\u003C Class II mobility",{"count":501,"type":24},30,[27],"In the last decade, progressive developments in computer hardware, software, manufacturing technologies, and dental materials consistently enhanced the use of digital technologies in dentistry. Traditional prosthodontic techniques have relied on manual fabrication processes, which often resulted in challenges such as suboptimal prosthesis fit, compromised occlusal stability, and limited customization options. However, the advent of 3D printing technology has revolutionized the field, offering new possibilities for patient-specific prosthodontic rehabilitation.\n\nAn accurate maxillomandibular relationship between the maxillary and mandibular casts is fundamental to prosthodontic practice. In the integration of intraoral scanners (IOSs) for different dental interventions, the accuracy of the digitizing methods recording the maxillomandibular relationship is similarly essential. The maxillomandibular relationship accuracy recorded by using IOSs has been analyzed in various in vitro and clinical studies.\n\nIntraoral digital scans are recorded in an unload condition, with the mouth open, while acquiring the maxillary and the mandibular intraoral scans. This condition changes when capturing the virtual occlusal records at maximum intercuspation position (MIP). Occlusal collisions are caused by the tooth location discrepancy resulting from the periodontal ligament plasticity between the recording of the intraoral digital scans and the virtual occlusal records, as well as from the intraoral scanning distortion and alignment procedures.\n\nArtificial intelligence driven program software and occlusal collisions or mesh interpenetrations tools have been proposed to improve the maxillomandibular relationship of the scanned models. The software programs of the IOSs can automatically eliminate the occlusal collisions present in virtual articulated casts. Similarly, dental computer-aided design (CAD) programs can automatically detect and eliminate occlusal collisions among the articulated intraoral digital scans imported. However, the effect of the occlusal collision corrections performed by using IOSs or CAD programs on the occlusal adjustment of the restorations is unknown.",[505,506],"Restoration Design","Digital Occlusal Collision",[508,509,510,511],"Artificial intelligence","Prosthodontics","Automated Design","Occlusion Collusion",{"date":487,"type":52},{"date":514,"type":24},"2026-01-25",{"date":516,"type":24},"2027-06-25",{"name":58,"class":59},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":525,"enrollmentInfo":526,"targetDuration":4,"studyType":25,"phases":528,"briefSummary":529,"conditions":530,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":60},"100616351","effects-of-sevoflurane-versus-desflurane-anesthesia-under-protective-mechanical-ventilation-for-robotic-assisted-surgery-100616351","NCT07304479","Effects of Sevoflurane Versus Desflurane Anesthesia Under Protective Mechanical Ventilation for Robotic Assisted Surgery","Effects of Sevoflurane Versus Desflurane Anesthesia Under Protective Mechanical Ventilation for Robotic Assisted Surgery on Airway Plateau Pressure: a Randomized, Prospective, Blinded Pilot Study","Inclusion Criteria:\n\n* Age 18 to 87 years\n* Undergoing elective robotic-assisted abdominal surgery\n* ASA physical status I-III\n\nExclusion Criteria:\n\n* ASA IV or V\n* Emergency surgery\n* Renal insufficiency\n* Clinically significant respiratory disease\n* Cardiomyopathy\n* Uncontrolled hypertension","87 Years",{"count":527,"type":24},50,[27],"Inhalational anesthetics, when used in abdominal surgery, offer advantages of lung protection and reduced alveolar inflammation. There is little literature, however, in the comparative use of sevoflurane versus desflurane anesthesia in patients undergoing abdominal robotic-assisted surgery and their effects on lung mechanics.",[531,532],"Respiratory Mechanics","Intraoperative","2025-12-12",{"date":535,"type":52},"2025-12-26",{"date":537,"type":52},"2025-05-01",{"date":539,"type":24},"2026-02-28",{"name":58,"class":59},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":19,"minAge":548,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":25,"phases":550,"briefSummary":551,"conditions":552,"keywords":554,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":60},"100615749","early-phase-1-prolotherapy-in-acupoints-in-chronic-non-specific-low-back-pain-clbp-100615749","NCT07296653","Prolotherapy in Acupoints in Chronic Non-specific Low Back Pain (cLBP)","Efficacy of Prolotherapy in Acupoints in Chronic Non-specific Low Back Pain (cLBP) - A Randomized Control Trial","Inclusion Criteria:\n\n* Body Mass Index (BMI) up to 45 kg\u002Fm2\n* Diagnoses corresponding to \\>1 of the following ICD-10 (International Classification of Diseases):\n\n  1. M51.3 Degeneration of intervertebral discs\n  2. M54.5 Low back pain\n  3. M54.8 Other forms of back pain\n  4. M54.9 Various forms of back pain\n  5. S33.5 Sprain of the lumbar spine\n  6. S33.6 Sprain of sacroiliac joint\n  7. S33.7 Sprain of other and various parts of lumbar spine and pelvis\n* Diagnosis of chronic nonspecific low back pain: Chronic nonspecific low back pain refers to pain in the lower back with or without radiation to the lower extremities, lasting for more than 3 months and not attributable to a specific anatomical structure or pathology on imaging, for example generalized degenerative changes, but no pathological findings (such as spinal stenosis or disorders of the sagittal\u002Fcoronal architecture or intervertebral foramen stenosis) with neurological deficits and no symptoms specific to the predominant pathology.\n* Numerical Rating Scale (NRS) \\> 3\u002F10 for at least 3 months prior to the study\n* Positive response to \\>1 muscle strength assessment tests in chronic low back pain A. prone plank bridge test (PBT) B. side bridge test (SBT) C. supine bridge test (SUBT) D. Range of Motion (ROM) E. Back Performance Scale (BPS) F. Straight leg raise test (SLR)\n* Pain, inability to walk, and stiffness in the lumbar spine, persisting for at least three months prior to the study.\n* Radiological imaging tests such as MRI or CT and, in cases of clinical suspicion (where appropriate), X-rays with dynamic flexion\u002Fextension or whole spine X-rays.\n* Signing of written consent prior to the injection of pharmaceutical agents.\n\nExclusion Criteria:\n\n* Any infection of the skin of the lumbar spine area, such as cellulitis, or periarticular or intra-articular infection or spondylodiscitis during the last 3 months\n* History of periarticular or intra-articular injection in the LMS with corticosteroids, local anesthetic, hyaluronic acid, radiofrequency application, electroacupuncture, or prolotherapy within the last three months.\n* Previous surgery (e.g., spinal fusion) in the LMS\n* Oral corticosteroids for low back pain or uncontrolled opioids\n* History of the following diseases:\n\n  1. connective tissue disease affecting the intervertebral spaces\n  2. insulin-dependent diabetes mellitus without adequate control\n  3. acute lumbosacral radiculopathy or peripheral neuropathy\n  4. neurological\u002Fpsychiatric disease\n  5. history of malignancy in the area or any other active malignancy in the body\n  6. Bleeding disorder\n  7. Trauma during the previous three months without imaging investigation\n  8. Systemic diseases such as rheumatic diseases\n  9. Known abdominal aortic aneurysm\n* Pregnancy (based on history)\n* History of allergy to local anesthetics\n* Needle phobia\n* Inability to communicate adequately, severe hearing loss, language problems, dementia\n* Inability to guarantee transportation to the hospital for treatments\u002Ffollow-up examinations","35 Years",{"count":23,"type":24},[292],"Chronic non-specific low back pain (CNSLBP) is among the most prevalent causes of disability on the planet, which often proves to be refractory to conventional pharmacological, interventional, and rehabilitation approaches. Although acupuncture has also shown analgesic effectiveness, its variability and reliance on practitioner skill limit its universal introduction into Western medical practice. Prolotherapy, an emerging regenerative injection treatment with hypertonic dextrose solutions, has been of potential benefit in managing musculoskeletal pain by triggering tissue repair and controlling neurogenic inflammation. Interestingly, several acupuncture points correspond to neuroanatomically relevant sites.\n\nThis single-blind randomized controlled trial aims to ascertain whether combinational prolotherapy with dextrose 15% and lidocaine 1% is superior to lidocaine 1% in patients with CNSLBP. Sixty patients will be allocated randomly into two equal-sized groups and receive a maximum of 15 ultrasound-guided injections into standardized acupoints of the lumbar area (BL23, BL25, BL31, BL54, GV3, GV4, and Ashi points) during three treatment sessions. Outcomes will be evaluated using the Numeric Rating Scale (NRS), the Oswestry Disability Index (ODI), the TUG (Timed Up and Go) test, the BPI (Brief Pain Inventory) scale, the Rolland-Morris Low Back Pain Disability Questionnaire and the Global Impression of Pain Questionnaire at baseline, and at 15, 30, and 90 days post-treatment.\n\nOutcomes should clarify whether dextrose-enhanced prolotherapy provides improved analgesia and functional return in comparison with local anesthetic injection alone. This study can present an uncomplicated, low-cost, and integrative regimen for CNSLBP with significant clinical and socioeconomic implications.",[553],"Chronic Non-specific Low Back Pain",[555,556,557,558],"prolotherapy","acupoints","dextrose","low back pain","2025-12-08",{"date":487,"type":52},{"date":562,"type":52},"2025-12-01",{"date":564,"type":24},"2027-02",{"name":58,"class":59},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":19,"minAge":573,"maxAge":4,"enrollmentInfo":574,"targetDuration":4,"studyType":25,"phases":575,"briefSummary":576,"conditions":577,"keywords":582,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":592,"locationsCount":60},"100611787","perineural-prolotherapy-in-chronic-knee-osteoarthritis-pain-100611787","NCT07245121","Perineural Prolotherapy in Chronic Knee Osteoarthritis Pain.","Perineural Prolotherapy in Chronic Knee Osteoarthritis Pain: A Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients of both sexes\n2. Age \\>38 years\n3. Body Mass Index (BMI) up to 42 kg\u002Fm2\n4. Diagnosis of knee osteoarthritis, according to the clinical criteria of the American College of Rheumatology. Osteoarthritis if the following combinations are present:\n\n   A, B, C, D or A, B, E or A, D, E:\n\n   A) Knee pain most days of the previous month B) Cracking during active joint movement C) Morning stiffness lasting at least 30 minutes D) Age at least 38 years E) Bone swelling of the affected knee on physical examination\n5. Chronic knee pain on the Numerical Rating Scale (NRS) \\> 5 for at least 3 months prior to the study\n6. Grade 2 or 3 osteoarthritis, according to the Kellgern-Lawrence classification\n7. Pain, creaking, and stiffness in the knee joint that persists for at least three months prior to the study.\n\nExclusion Criteria:\n\n1. Any infection of the skin of the knee joint, such as cellulitis, or periarticular or intraarticular infection during the last 3 months\n2. Poorly controlled diabetes mellitus or connective tissue disease affecting the knee joint\n3. History of previous total knee arthroplasty or other knee surgery.\n4. History of periarticular or intraarticular injection of corticosteroids, local anesthetic, hyaluronic acid, platelet-rich plasma, radiofrequency, prolotherapy within the last trimester\n5. History of knee injury or fracture within the last 3 months\n6. History of acute lumbosacral radiculopathy or peripheral neuropathy, neurological, psychiatric disease\n7. Pain limited in the posterior aspect of the knee\n8. History of limb malignancy\n9. History of bleeding disorder\n10. Pregnancy\n11. Allergy to local anesthetics, needle phobia\n12. Difficulty communicating (severe hearing loss, dementia, language problems)\n13. Non-guaranteed transportation to hospital for treatments and re-evaluations","38 Years",{"count":23,"type":24},[27],"The aim of this study is to test whether the addition of dextrose to perineural injections is superior to local anesthetic alone, as some initial data have indicated. To enhance the potential therapeutic effect, we will proceed to a 4-point injection technique, targeting 4 genicular nerves (superomedial, superolateral, inferomedial, recurrent peroneal genicular nerve) in a randomized controlled trial with two arms.",[578,579,580,581],"Chronic Pain","Perineural Analgesia","Prolotherapy","Knee Osteoarthritis",[583,584,585],"Perineural prolotherapy","Knee osteoarthritis","Chronic pain","2025-11-30",{"date":588,"type":52},"2025-12-02",{"date":590,"type":52},"2025-11-24",{"date":564,"type":24},{"name":58,"class":59},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":25,"phases":601,"briefSummary":602,"conditions":603,"keywords":605,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":60},"100598871","evaluation-of-the-systemic-burden-of-non-surgical-periodontal-therapy-a-randomized-clinical-trial-on-five-different-treatment-protocols-100598871","NCT07077122","Evaluation of the Systemic Burden of Non-surgical Periodontal Therapy: A Randomized Clinical Trial on Five Different Treatment Protocols","Inclusion Criteria:\n\n* Periodontitis stage III or IV\n* Non-smokers or light smokers (\\\u003C10 cigarettes\u002Fday)\n* No NSAIDs in regular basis or antibiotics 3 months before\n* No previous periodontal treatment 12 months before\n* No presence of other acute or chronic infections\n* No systemic disease or medication known to affect the serum level of inflammatory markers (cyclooxygenase inhibitors, platelet aggregation inhibitors, lipid lowering agents, â-adrenoreceptor antagonists, angiotensin converting enzyme inhibitors, antidiabetic agents, estrogen-based medications, medication for autoimmune disease, magnesium or vitamin E supplements)\n* No pregnancy or lactation\n* Written informed consent.",{"count":600,"type":24},75,[27],"Periodontitis is a chronic inflammatory disease of the periodontal tissues leading to the destruction of the tooth supporting structures. Despite the fact that periodontal bacteria are etiological agents, host susceptibility related to the inflammatory response to plaque bacteria is the main determinant of the development of periodontitis. Non-surgical periodontal therapy (NSPT) represents the base of any therapeutic approach. Its main component is the removal of bacterial deposits, i.e. soft biofilm or mineralized calculus, from the tooth surface via mechanical debridement.\n\nIt is well established that patients suffering from periodontitis present with a low-grade systemic inflammatory state when compared to healthy subjects. Increased concentrations of inflammatory biomarkers in systemic circulation, such as, C-reactive protein (CRP) and interleukin (IL)-6, have already been reported. A significant amount of evidence derived from epidemiological as well as experimental studies has implicated periodontitis as a putative risk factor for a number of systemic diseases, such as, cardiovascular diseases, diabetes and respiratory diseases having systemic low-grade inflammation as their underlying pathogenic mechanism. Furthermore, several intervention studies provide evidence that periodontal treatment may improve systemic inflammatory markers and potentially reduce the risk for cardio-metabolic diseases.\n\nHowever, periodontal therapy may pose a transient, short-term health hazard immediately after instrumentation of the root surface presumably due to the spill of bacteria and their products in the systemic circulation and the subsequent acute inflammatory response. Positive bacteremia in NSPT ranges from 13% to 80.9% after mechanical debridement depending primarily on the periodontal status of the patient, but also on the study design and the microbiological methodology.\n\nFinally, an important aspect concerning NSPT is method and duration of delivery. NSPT may be carried out with either hand instruments, power driven instruments, such as, ultrasonic and sonic or a \"blended approach\" using both. Besides these instruments, the adjunctive use of lasers or\u002Fand air powder technology has been proposed. Regarding duration, treatment may be staged over several visits with a quadrant approach, or with a full-mouth debridement approach, also referred to as an intensive treatment approach, which delivers complete debridement within 24 hours.\n\nThe aim of this clinical trial is to assess the immediate systemic burden of five different treatment protocols for the NSPT on:\n\n1. bacteremia\n2. serum inflammatory responses. Additionally, saliva CRP levels will be assessed and compared to serum. Moreover, the effectiveness of the treatment protocols on clinical periodontal parameters will be assessed.",[604],"Periodontitis",[606,607,608,609],"periodontitis","inflammatory markers","non-surgical periodontal therapy","bacteremia","2025-08-27",{"date":612,"type":52},"2025-09-04",{"date":614,"type":52},"2025-08-25",{"date":616,"type":24},"2027-12-15",{"name":58,"class":59},{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":4,"enrollmentInfo":625,"targetDuration":261,"studyType":73,"phases":4,"briefSummary":627,"conditions":628,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":60},"100585497","clinical-study-to-evaluate-the-effects-of-the-complement-c5-inhibitor-ravulizumab-on-serum-neurofilament-light-chain-snfl-and-glial-fibrillary-acidic-protein-sgfap-levels-in-patients-with-aquaporin-4-positive-aqp4-ab-neuromyelitis-optica-spectrum-disorder-nmosd-100585497","NCT06903130","Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)","An Exploratory, Non-Interventional, Prospective, Multicenter, Nationwide, Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)","Inclusion Criteria\n\nPatients are eligible to be included in the study only if all of the following criteria apply:\n\nAge\n\n1. Patient must be 18 years of age or older, at the time of signing the informed consent.\n\n   Type of Patient and Disease Characteristics\n2. Anti-AQP4 Ab-positive at screening and a diagnosis of NMOSD as defined by the 2015 international consensus diagnostic criteria (Wingerchuk, 2015). A historically positive anti-AQP4 Ab test may be acceptable if the test was performed using an acceptable, validated cell-based assay from an accredited laboratory.\n3. At least 1 clinical attack prior to the Prescreening\u002FScreening Periods.\n4. Treatment-naïve patients or patients under specific off-label treatments (rituximab, corticosteroids, azathioprine, mycophenolate mofetil) or the complement C5 inhibitor ravulizumab. Naïve patients who initiate ravulizumab at enrolment, should have been prescribed ravulizumab, but not yet initiated treatment, according to the label and local market reimbursement criteria.\n5. Vaccinated against N. meningitidis (for serogroups A, C, W, Y and B) a) within 3 years and at least 2 weeks prior to the first dose of ravulizumab, or b) at the time of the first dose of ravulizumab provided that antibacterial drug prophylaxis is administered as per National Vaccination Guidelines and Summary of Product Characteristics of ravulizumab.\n\n   Weight\n6. Body weight ≥ 40 kg.\n\n   Sex\n7. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those receiving each immunotherapy.\n\n   Informed Consent\n8. Capable of giving signed informed consent as described in Section 10.1.3, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion Criteria\n\nPatients are excluded from the study if any of the following criteria apply:\n\nMedical Conditions\n\n1. History of N. meningitidis infection.\n2. Human immunodeficiency virus (HIV) infection (evidenced by HIV-1 or HIV-2 antibody titer)\n3. History of unexplained infections.\n4. Active systemic bacterial, viral, or fungal infection within 14 days prior to screening.\n5. Presence of fever ≥ 38°C (100.4°F) within 7 days prior to screening\n6. NMOSD pregnant women will be excluded according to the local clinical practice. '\n7. History of implanted medical devices which are incompatible with strong magnetic fields used for MRI.\n\nPrior\u002FConcomitant Therapy 6. Use of inebilizumab within 6 months prior to Enrollment in patients switching to another therapy i.e. ravulizumab or the off-label ISTs.\n\n7\\. Use of satralizumab within 3 months prior to Enrollment. 8. Pregnant, breastfeeding, or intending to conceive during the course of the study",{"count":626,"type":24},40,"This is a nationwide observational study looking at how ravulizumab, a complement C5 inhibitor, affects blood biomarkers o sNfL and sGFAP in people with AQP4-antibody positive NMOSD. The study does not change your treatment-only regular blood samples are collected to monitor these markers",[629],"NMOSD","2025-06-30",{"date":632,"type":52},"2025-07-01",{"date":634,"type":24},"2025-09-01",{"date":636,"type":24},"2028-06-01",{"name":58,"class":59},{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":19,"minAge":69,"maxAge":235,"enrollmentInfo":646,"targetDuration":4,"studyType":25,"phases":647,"briefSummary":648,"conditions":649,"keywords":654,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":60},"100588829","first-local-anaesthesia-thoracoscopy-for-pleural-effusion-diagnosis-100588829","NCT06946498","First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.","Local Anesthesia Thoracoscopy as a First Line Approach in the Diagnosis of Suspected Malignant Pleural Effusion: FLAT Trial.","FLAT","Inclusion Criteria:\n\n* Undiagnosed pleural effusion with the character of a lymphocytic exudate\n\nExclusion Criteria:\n\n* Empyema\n* Transudate pleural effusion.\n* Central airway obstruction by tumor.\n* Existence of extensive adhesions that do not allow the development of iatrogenic pneumothorax and the safe entry of the thoracoscope.\n* Uncontrollable cough.\n* Acute respiratory failure and\u002For Hypercapnia.\n* Performance Status: 5",{"count":177,"type":24},[27],"Non randomized study with two groups. The study group includes patients with suspected malignant pleural effusion, in whom the investigation of pleural effusion begins directly with pleural biopsy by Local Anesthesia Thoracoscopy (LAT).\n\nThe Control Group includes patients who come to the same hospital and are treated with the Standard of Care (SOC) strategies were used. Efficacy of LAT, Sensitivity, Hospitalization, time to diagnosis and general safety and comfort of the groups' subjects will be assessed.",[650,651,652,653],"Suspected Malignant Lung Neoplasm","Pleural Effusion","Pleural Effusion, Malignant","Mesothelioma, Malignant",[655,656,657,658,659,660],"Malignant Pleural Effusion","Local Anesthesia Thoracoscopy","Medical Thoracoscopy","Lung cancer","Mesothelioma","Lymphocytic Exudate","2025-04-20",{"date":663,"type":52},"2025-04-27",{"date":665,"type":52},"2023-05-23",{"date":667,"type":24},"2026-12-31",{"name":58,"class":59},{"id":670,"slug":671,"hasResults":12,"nctId":672,"briefTitle":673,"officialTitle":674,"acronym":4,"eligibilityCriteria":675,"healthyVolunteers":12,"sex":19,"minAge":676,"maxAge":677,"enrollmentInfo":678,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":679,"conditions":680,"keywords":682,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":686,"lastUpdatePostDateStruct":687,"startDateStruct":689,"completionDateStruct":691,"leadSponsor":693,"locationsCount":60},"100586719","effect-of-advanced-hybrid-closed-loop-system-minimed-780g-in-newly-diagnosed-children-and-adolescents-with-type-1-diabetes-on-glycemic-control-and-patient-reported-outcomes-compared-to-standard-insulin-therapy-historical-data-ahcl-in-new-onset-t1d-children-study-100586719","NCT06919029","Effect of Advanced Hybrid Closed Loop System, MiniMed 780G in Newly Diagnosed Children and Adolescents With Type 1 Diabetes on Glycemic Control and Patient Reported Outcomes Compared to Standard Insulin Therapy Historical Data (AHCL in New Onset T1D Children Study)","Assessing the Effect of Advanced Hybrid Closed Loop System, MiniMed 780G With GS4 Glucose Sensor in Newly Diagnosed Children and Adolescents With Type 1 Diabetes on Glycemic Control and Patient Reported Outcomes Compared to Standard Insulin Therapy Historical Data (AHCL in New Onset T1D Children Study): a Single Arm Open- Label Prospective Observational Study Protocol","Inclusion Criteria:\n\n1. Clinical diagnosis of type 1 diabetes (WHO criteria). Diagnosis of type 1 diabetes is based on international criteria and the investigator's judgment; C peptide level and antibody determinations are not required.\n2. Age range 7 to 17 years.\n3. Literate in Greek or English.\n4. Willing to wear study devices.\n5. Willing to follow study-specific instructions.\n6. Total daily insulin dose greater than 8.0 units over 1 week period\n7. Willing and able (access to internet from home) to download information into the Medtronic CareLink software\n8. Clinically eligible to start the AHCL system\n\nExclusion Criteria:\n\n* Type 2 diabetes mellitus or MODY diabetes\n* Any untreated comorbidities of type 1 diabetes\n* Medication affecting metabolic control or interfering in the interpretation of HbA1c\n* Pregnancy\n* Untreated diabetes retinopathy, or other causes that in the investigator's opinion, precludes the individual from participating in the trial.\n* Known or suspected allergy to insulin.\n* Regular use of acetaminophen.\n* Lack of reliable telephone facility for contact.\n* Living alone.\n* Severe visual or hearing impairment.\n* Medically documented allergy to the adhesive of plasters or unable to tolerate tape adhesive around sensor placement.\n* Serious skin lesions at areas of the body used for insertion of the glucose sensor.\n* Illicit drugs abuse.\n* Alcohol abuse.\n* Sickle cell disease, haemoglobinopathy, receiving red blood cell transfusion or erythropoietin within 3 months prior to time of enrollment.\n* Eating disorder including anorexia\u002Fbulimia.\n* Milk protein allergy.","7 Years","17 Years",{"count":501,"type":24},"The objective of this study is to evaluate glycemic control of users of the AHCL system MiniMed 780G with GS4 calibration-free sensor in children and adolescents with newly diagnosed T1D implemented directly upon T1D diagnosis in combination with continuous glucose monitoring system (CGMS) compared with those treated with MDI retrieved from historical data- in a single- arm open-label prospective observational study, assessed at 3 months. After the initial study period there will be a 3month extension phase of the study.",[681],"Diabetes Mellitus, Type I",[683,684,685],"type 1 diabetes","advanced hybrid closed loop","diabetes onset","2025-04-02",{"date":688,"type":52},"2025-04-09",{"date":690,"type":24},"2025-04",{"date":692,"type":24},"2026-04",{"name":58,"class":59},{"id":695,"slug":696,"hasResults":12,"nctId":697,"briefTitle":698,"officialTitle":699,"acronym":700,"eligibilityCriteria":701,"healthyVolunteers":12,"sex":702,"minAge":69,"maxAge":703,"enrollmentInfo":704,"targetDuration":4,"studyType":25,"phases":706,"briefSummary":707,"conditions":708,"keywords":710,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":726,"lastUpdatePostDateStruct":727,"startDateStruct":729,"completionDateStruct":731,"leadSponsor":733,"locationsCount":60},"100586204","transcutaneous-vagus-nerve-stimulation-on-fibromyalgia--double-blind-sham-controlled-randomized-clinical-trial-100586204","NCT06912334","Transcutaneous Vagus Nerve Stimulation on Fibromyalgia- Double-blind, Sham-controlled Randomized Clinical Trial","Investigation of the Effects of Transcutaneous Vagus Nerve Stimulation on Fibromyalgia. A Double Blind, Sham-controlled Randomized Clinical Trial","TVNS- Fibro","Inclusion Criteria\n\n* Women between 18-79 years old\n* Women diagnosed with Fibromyalgia according to the ACR 2016 Revised Classification Criteria\n* Moderate to high pain intensity according to analog pain scales (above 4 points over 10), for more than 6 months\n* Cognitive function sufficient to understand the experiments and follow instructions\n* Ability to read and understand all information on the device display.\n* Ability to adjust the strength of the stimulation or give feedback regarding their response to the device (feeling tingling\u002Fpulsating\u002Fpain).\n* Ability to comply with the recommended therapy regiment of 30 min per day.\n* The ear electrode needs to fit the patient.\n* Patients with physical or mental disabilities\n* The patient must be able to use the device by themselves or\n* The patients' caretaker can operate the device on the patient. In this case the patient --must still be able to give feedback regarding their response to the device\n\nExclusion Criteria\n\n* Cardiac arrhythmias\n* Pregnancy\n* Serious mental disorder (dipolar disorder, schizophrenia etc.)\n* Prior injury to the vagus nerve\n* Individuals with scar tissue that may interfere with the stimulation\n* Presence of an electrically or magnetically activated implant","FEMALE","79 Years",{"count":705,"type":24},120,[27],"Stimulation of the vagus nerve, a parasympathetic nerve that controls the digestive, the vascular and immune systems, produces pain relief in various clinical conditions. Transmission via vagal afferents to the nucleus of the solitary tract has been proposed as the primary physiological mechanism that reduces pain intensity following vagal stimulation. Medication is one of the pillars of dealing with chronic pain, with several benefits, but also side effects. Fibromyalgia is an idiopathic chronic pain syndrome with few, effective and safe treatments. However, current research in the field of vagal innervation suggests psychophysiological and electrical ways by which the syndrome may be treated.The chronic pain symptoms of fibromyalgia patients may benefit from vagus nerve stimulation, by normalizing the autonomic and immune system dysfunction that causes their respective symptoms. However, the effects of multiple sessions of transcutaneous vagus nerve stimulation (tVNS) in fibromyalgia have not been evaluated in randomized clinical trials. The hypothesis of our study is to evaluate if the addition of transcutaneous stimulation of the auricular branch of the vagus nerves in patients with fibromyalgia, can lead to better pain control and quality of life. We will offer a 2-week treatment (14 sessions of 30 minutes) in a randomized double-blind controlled trial. The sample of the study, which will be conducted in the pain clinic of the Aretaieion University General Hospital, will be consisted of 120 patients, who will be divided into 2 groups (1st group: standard pharmacological treatment + active tVNS, 2nd group: standard pharmacological treatment + sham tVNS). The study is designed to determine, if standard pharmacological treatment combined with 14 sessions of tVNS is able to improve pain symptomatology in fibromyalgia and all symptoms of this syndrome, by using appropriate scales. This study examines a new and potentially impactful way to address a major public health issue where prevalence is high in given groups, its impact is multidimensional and treatment options are limited. The holistic treatment of chronic pain, including its neurobiological, cognitive, behavioral and psychological components, may become a valuable aid in the completion of the research project, with the ultimate aim of the study being the establishment of non-invasive stimulation of the vagus nerve for the treatment of chronic pain in clinical practice in the future.",[709],"Transcutaneous Vagus Nerve Stimulation on Fibromyalgia",[711,712,713,714,715,716,717,718,719,720,721,722,723,724,725],"vagus nerve","vagus nerve stimulation","tVNS","transcutaneous vagus nerve stimulation","fibromyalgia","FM","double blind","sham controlled","randomized clinical trial","pain","depression","sleep disorders","fatigue","fibro fog","2016 revised FM ACR Classification Criteria","2025-03-30",{"date":728,"type":52},"2025-04-04",{"date":730,"type":52},"2024-10-15",{"date":732,"type":24},"2026-06-01",{"name":58,"class":59},""]